What are we learning from early-phase clinical trials with glutamate targeting medications for the treatment of major depressive disorder

JAMA Psychiatry

Volumn 73, Issue 7, 2016, Pages 651-652

  Sanacora, Gerard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIMGLURANT; GLUTAMATE RECEPTOR 5; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; EDITORIAL; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PHASE 2 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HUMANS;

EID: 84978100390     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.0780     Document Type: Editorial

References (11)

1. ∗D): lessons learned. J Clin Psychiatry. 2008;69(7):1184-1185.
2. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437.
3. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950-966.
4. Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial [published online June 15, 2016]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.0838.
5. Tebano MT, Martire A, Rebola N, et al. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J Neurochem. 2005;95(4):1188-1200.
6. Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Curr Opin Neurobiol. 2016;36:112-117.
7. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631-637.
8. Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978-985.
9. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140-149.
10. Cerecor. Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder. http://www.cerecor.com/news-publications/news-2015-03-20.php. Accessed May 5, 2016.
11. Pathak S, Su H-L, Posener J. et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: post-hoc analyses of a randomized, placebo-controlled study (PURSUIT). Poster presented at the American Society of Clinical Psychiatry Annual Meeting; June 16-19, 2014; Hollywood, Florida.